Curr Hypertens Rep. 2026 Nov 12;28(1):50. doi: 10.1007/s11906-026-01395-2.
ABSTRACT
PURPOSE OF COMMENTARY: Chronic kidney disease (CKD) has almost never been counted as an important incident endpoint in randomized clinical trials (RCTs) in the prevention of complications and outcomes in essential hypertension but rather included in broader safety assessments. Although target systolic blood pressure (SBP) < 130 and even < 120 mmHg is recommended by some guidelines, it is unclear whether such aggressive treatment has a favorable effect on hypertension-related decline of CKD.
NEW OBSERVATIONS: During the past two decades several RCTs have been performed with patients randomized to more aggressive SBP target vs. SBP target closer to standard treatment. Several large RCTs have targeted and/or otherwise achieved SBP as low as 120 mmHg or maybe even lower in fractions of middle-aged and older high risk essential hypertensive people with major worsening of kidney function. However, other RCTs showed neutral effects or even reduction in kidney endpoints with achieved SBP below 130 mmHg and possible benefit in preventing cardiovascular outcomes though inclusion of soft endpoints in some trials diluted the cardiovascular message. Intensive BP lowering is associated with greater declines in kidney function in all major RCTs investigating target SBP < 120 mmHg. The long-term clinical significance of these changes must be interpreted alongside possible cardiovascular risks. Hence, one should aim at a SBP target < 130 mmHg in middle-aged and older hypertensive patients if the treatment is otherwise well tolerated. The benefits of low SBP targets in patients who develop CKD should be reassessed in the context of new available treatments providing kidney protection such as SGLT2-inhibitors, aldosterone antagonists and GLP1-agonists.
PMID:43018673 | PMC:PMC13759575 | DOI:10.1007/s11906-026-01395-2

